Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Hamid on Potential Combinations With Docetaxel in mHSPC Subtypes

April 30th 2020

Anis Hamid, MBBS, discusses potential combination with docetaxel in metastatic hormone-sensitive prostate cancer subtypes.

Dr. Sawyers on the Negative Results of the IMbassador250 Trial in mCRPC

April 30th 2020

Charles L. Sawyers, MD, discusses the negative results on the IMbassador250 trial in metastatic castration-resistant prostate cancer.

Dr. Chang on Efforts to Improve Quality of Life in Prostate Cancer

April 30th 2020

Sam S. Chang, MD, MBA, discusses the importance of quality of life in prostate cancer.

Dr. Armstrong on the utility of PARP Inhibitors in Mutated Prostate Cancer

April 30th 2020

Andrew J. Armstrong, MD, discusses the utility of PARP inhibitors in mutated prostate cancer.

Olaparib Pivotal mCRPC Data Published in NEJM as FDA Weighs Approval

April 29th 2020

Findings from the pivotal phase 3 PROfound trial of olaparib as a treatment for men with metastatic castration-resistant prostate cancer harboring homologous recombination repair (HRR) gene alterations were published in the New England Journal of Medicine.

Dr. Fendler on Impact of 68Ga-PSMA-11 PET on Prostate Cancer Management

April 29th 2020

Wolfgang Fendler, MD, discusses the utility and pending FDA approval of 68Ga-PSMA-11 PET in prostate cancer.

Dr. Lee on Choosing Among Antiandrogens in Nonmetastatic CRPC

April 29th 2020

Richard (Rick) JaeBong Lee, MD, PhD, discusses choosing among the antidrogens available in the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Dr. Beltran on the Limitations of Tissue Biopsies Versus Liquid Biopsies in CRPC-NE

April 29th 2020

Himisha Beltran, MD, discusses the limitations of tissue biopsies versus liquid biopsies in castration-resistant neuroendocrine prostate cancer.

Dr. Agarwal on the Tolerability of Apalutamide in mCSPC

April 29th 2020

Neeraj Agarwal, MD, discusses the tolerability of apalutamide in metastatic castration-sensitive prostate cancer.

Dr. Shinohara on Radiation Therapy Considerations in Prostate Cancer

April 28th 2020

Eric Shinohara, MD, MSCI, discusses radiation therapy considerations for patients with prostate cancer.

Dr. Parker on the Optimal Timing of Salvage Therapy in Prostate Cancer

April 27th 2020

Chris Parker, MD, discusses the optimal timing of salvage radiotherapy for men with prostate cancer.

Dr. Concepcion on Current Testing Patterns in Urology Practices

April 25th 2020

Raoul S. Concepcion, MD, FACS, director, Comprehensive Prostate Center, discusses current testing patterns in urology practices.

Dr. Mohler on Recommendations for Genetic Testing in Prostate Cancer

April 25th 2020

James L. Mohler, MD, professor of oncology, associate director, and senior vice president of Translational Research, chief of Inter-Institutional Academics at Roswell Park Comprehensive Cancer Center, discusses recommendations for performing genetic testing in prostate cancer.

Dr. McKay on Evaluating Radium-223 in HRD-Mutant mCRPC

April 25th 2020

Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses planned research in which investigators will evaluate the use of radium-223 dichloride (Xofigo) in patients with homologous recombination deficiency (HRD)-mutant metastatic castration-resistant prostate cancer (mCRPC).

Dr. Beltran on Using cfDNA to Detect Castration-Resistant Neuroendocrine Prostate Cancer

April 25th 2020

Himisha Beltran, MD, discusses profiling of circulating tumor DNA to detect castration-resistant neuroendocrine prostate cancer.

Sipuleucel-T Plus Radium-223 Improves Clinical Outcomes in Bone-Metastatic CRPC

April 24th 2020

Emmanuel S. Antonarakis, MBBCh, discusses the efficacy of radium-223 plus sipuleucel-T in patients with bone-metastatic castration-resistant prostate cancer and the next steps for research for this combination.

Olaparib Improves Survival in HRR-Mutant mCRPC

April 24th 2020

Olaparib improved overall survival in previously treated patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene mutations.

Dr. Hamid on Next Steps for Precision Medicine in mHSPC

April 24th 2020

Anis Hamid, MBBS, discusses next steps for precision medicine in metastatic hormone sensitive prostate cancer.

Dr. Hwang on the Utility of Docetaxel in mCSPC

April 24th 2020

Clara Hwang, MD, discusses the utility of docetaxel and abiraterone acetate in metastatic castration-sensitive prostate cancer.

Dr. Chang on Questions Regarding Molecular Testing in Prostate Cancer

April 23rd 2020

Sam S. Chang, MD, MBA, discusses remaining questions regarding molecular testing in prostate cancer.